MedTrace Logo

First in Human Study Evaluating Single Ascending Oral Doses of YCT-529 in Healthy Males

NCT06094283 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-10-02

No results posted yet for this study

Summary

A single ascending oral dose(s) study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of YCT-529 in healthy male subjects.

Conditions

  • Male Contraception

Interventions

DRUG

YCT-529

Single oral dose (planned doses of 10, 30, 90 and 200 mg; dose levels will not exceed 250 mg

DRUG

YCT-529 Placebo

YCT-529 Placebo

Sponsors & Collaborators

  • YourChoice Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Sharan Sidhu, MBChB · Quotient Sciences

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-20
Primary Completion
2024-06-18
Completion
2024-06-18

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06094283 on ClinicalTrials.gov